Effect of 6 months of benralizumab on peripheral blood gene expression
Severe asthma is characterized by persistent and uncontrolled symptoms despite high-intensity treatment. Benralizumab, an anti-IL5 receptor alpha monoclonal antibody, improves asthma symptoms and enhances the quality of life in severe asthmatic patients. However, factors influencing treatment response are poorly understood. This prospective observational study investigates gene expression patterns associated with benralizumab response in severe asthma. Here we show whole blood gene expression of 15 patients before treatment and after 6 months of treatment with benralizumab.